MHRA – Page 169 – Pharma.Tips

Data Integrity Risk during tech transfer: how to document for FDA/EMA/MHRA review

How to Navigate Data Integrity Risks During Tech Transfer for Compliance with FDA, EMA, and MHRA Data integrity risks during tech transfer present significant challenges for pharmaceutical manufacturers. With increasing…

API microbial limit failure during commercial scale manufacture: data integrity and chromatographic audit trail review steps

Addressing API Microbial Limit Failures During Commercial Scale Manufacture: A Comprehensive Investigative Approach Microbial contamination during the manufacturing of Active Pharmaceutical Ingredients (APIs) can lead to significant issues, including batch…

Cell viability failure during tech transfer: regulatory risk assessment and CAPA

“`html Assessing Cell Viability Failures During Tech Transfers: A Regulatory Risk Approach In the complex landscape of pharmaceutical manufacturing, especially concerning Advanced Therapy Medicinal Products (ATMPs), ensuring consistent cell viability…

Fill Volume Variability in ear drop manufacturing: packaging integrity and stability justification

Understanding Fill Volume Variability in Ear Drop Manufacturing: A Methodical Approach to Investigation Fill volume variability in ear drop manufacturing can significantly impact product quality, regulatory compliance, and patient satisfaction.…

Control Strategy Weakness for innovative delivery systems: risk assessment and validation impact analysis

Identifying Control Strategy Weaknesses in Innovative Delivery Systems: A Comprehensive Investigation In the realm of pharmaceutical manufacturing, ensuring the integrity of novel drug delivery systems is paramount. A control strategy…

Ivivc Mismatch after formulation change: regulatory-ready investigation and CAPA plan

Investigating Ivivc Mismatch Following a Formulation Change: A Regulatory-Ready Approach Pharmaceutical professionals often encounter the challenge of in vitro–in vivo correlation (IVIVC) mismatches after formulation changes, leading to potential regulatory…

API bulk density variability after solvent change in last step: how to justify reprocessing vs rejection to FDA/EMA inspectors

Investigating Variability in API Bulk Density After Last-Step Solvent Change: A Practical Guide for Compliance Justification In the highly regulated landscape of pharmaceutical manufacturing, variability in active pharmaceutical ingredients (APIs)…

Aseptic manipulation deviation during FDA inspection readiness: regulatory risk assessment and CAPA

Aseptic Manipulation Deviation During FDA Inspection Readiness: A Comprehensive Investigation Approach Aseptic manipulation deviations present significant risks during FDA inspections, especially concerning regulatory compliance. Such deviations can lead to serious…

Sedimentation Oos at accelerated stability: sanitation, water, and EM checks

Understanding Sedimentation OOS at Accelerated Stability: A Comprehensive Investigation Framework In the highly regulated pharmaceutical landscape, deviations and out-of-specification (OOS) results pose significant challenges. One such scenario is the observation…

Tag: MHRA